ARCHIVES

FDA Oncologic Drugs Advisory Committee: Trials In A Small Indication Tell Big Story About Pitfalls of Delaying Progression

This article is from The Cancer Letter archive.

Vol. 37 No. 15 | April 15, 2011

Download PDF Visit The Full Archive

Related Articles

CVS To Stop Tobacco Sales at Pharmacies

February 7, 2014

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

DCCR Free Up $5 Million; New Policy Limits Core Support

November 5, 1976

Sloan-Kettering Sues Empire Blue Cross Over Reimbursement

September 17, 1993

Celgene Signs CRADA With NCI For Development Of CDC-501.

June 30, 2000

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

January 12, 1979